Akums has received Indian marketing approval for a fixed treatment kit combining vonoprazan, clarithromycin and amoxicillin for adults with Helicobacter pylori infection.

Lupin has received Indian marketing approval for a pegfilgrastim biosimilar used to reduce the risk of chemotherapy-induced neutropenia.

The conditional marketing approval introduces a new intravenous abatacept biosimilar for patients with moderate to severe rheumatoid arthritis or active psoriatic arthritis who have responded inadequately to other disease-modifying treatments.

Meiji Seika Pharma group company KM Biologics and Serum Institute of India (SII) are collaborating to transfer technology for the development and manufacture in India of the Japanese encephalitis vaccine currently produced and marketed by KM Biologics in Japan. SII is expected to seek Indian regulatory approval as early as 2027, with the partnership intended to establish local manufacturing and supply of the vaccine for children in India.

The exclusive agreement expands Mankind Pharma's injectable diabetes portfolio with two long-acting insulin analogues while strengthening its strategy of in-licensing innovative therapies for the Indian market.